Genmab — August 2018
-
For lige at vende tilbage til D-RVd fra i går. Winkel sagde på CC at vi først ville få de fulde data fra Griffin i 2019. Men desuden sagde han (fra transcr.): but there could be further data from the so-called [indiscernible] part of that study at ASH this year. er nogen der ved, hvad det er for en del?
-
Vedrørende 12:47 (ofatumumab): https://ibj.pasteur.ac.ir/article-1-2213-en.pdf
-
Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling
Background: Ofatumumab, an anti-CD20 mAb, was approved in 2009 for the treatment of chronic lymphocytic leukemia. This mAb acts through immune-mediated mechanisms, in particular complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by natural killer cells as well as antibody-dependent phagocytosis by macrophages. Apoptosis induction is another mechanism of this antibody. Computational ...
(ibj.pasteur.ac.ir)
(daratumumab) for Front Line Multiple MyelomaHello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind